Syncom Formulations (India) Ltd Hits 52-Week Low at Rs.11.52

Stock Price Movement and Market Context

On 22 Jan 2026, Syncom Formulations (India) Ltd’s stock price touched Rs.11.52, its lowest level in the past year. This new low comes after a period of sustained downward pressure, although the stock showed a modest gain today, rising by 1.19%, yet still underperforming its sector by 0.48%. The stock remains below all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — indicating a persistent bearish trend.

In contrast, the broader market displayed mixed signals. The Sensex opened higher at 82,459.66, gaining 550.03 points (0.67%) but was trading slightly lower at 82,169.57 (down 0.32%) during the day. Despite the Sensex being 4.86% shy of its 52-week high of 86,159.02, it has experienced a three-week consecutive decline, losing 4.19%. Mid-cap stocks led the market rally with the BSE Mid Cap index gaining 0.94% today.

Syncom’s 52-week high was Rs.23.46, highlighting the steep decline of 50.9% from that peak to the current low. Over the last year, the stock has underperformed significantly, delivering a negative return of -34.47%, while the Sensex posted a positive return of 7.40% and the BSE500 index returned 6.94%.

Financial Performance and Growth Trends

Syncom Formulations’ long-term financial trajectory has been challenging. Over the past five years, net sales have contracted at an annual rate of -63.63%, while operating profit declined by -52.27%. These figures reflect a subdued growth environment for the company, contributing to its current valuation pressures.

Despite these declines, recent half-year results indicate some positive momentum. Net sales for the latest six months stood at Rs.238.62 crores, growing by 25.87%, while profit after tax (PAT) surged by 72.46% to Rs.32.32 crores. Operating profit also increased by 8.29%, marking the sixth consecutive quarter of positive results. The company’s return on capital employed (ROCE) for the half-year reached a high of 22.06%, and return on equity (ROE) was recorded at 16.6%, suggesting efficient utilisation of capital in recent periods.

Syncom’s debt profile remains conservative, with an average debt-to-equity ratio of just 0.05 times, indicating limited leverage and a relatively low financial risk.

Valuation and Market Perception

The stock currently trades at a price-to-book value of 2.9, which is a premium compared to its peers’ historical averages. This valuation reflects a fair assessment given the company’s recent profit growth, which has risen by 90.1% over the past year despite the stock’s negative price performance. The price-to-earnings-to-growth (PEG) ratio stands at 0.2, signalling that the market may be pricing in slower growth or other concerns.

Domestic mutual funds hold no stake in Syncom Formulations, a notable point given their capacity for detailed research and selective investment. This absence may indicate a cautious stance on the company’s prospects or valuation at current levels.

Mojo Score and Analyst Ratings

MarketsMOJO assigns Syncom Formulations a Mojo Score of 46.0, categorising it with a Sell grade as of 1 Aug 2025, a downgrade from its previous Hold rating. The company’s market cap grade is 3, reflecting its mid-tier size within the Pharmaceuticals & Biotechnology sector. This rating change underscores the tempered outlook on the stock’s near-term performance based on fundamental and market factors.

Summary of Key Metrics

To summarise, Syncom Formulations (India) Ltd’s stock has declined sharply over the past year, culminating in a 52-week low of Rs.11.52. The company’s financials show mixed signals, with long-term sales and operating profit contraction contrasting with recent improvements in profitability and capital efficiency. The stock’s valuation remains elevated relative to peers, while institutional interest is minimal. Market conditions, including a broadly fluctuating Sensex and sector performance, provide additional context to the stock’s price movements.

Conclusion

Syncom Formulations’ current share price reflects a complex interplay of historical underperformance, recent financial improvements, and cautious market sentiment. The stock’s position below all major moving averages and its 52-week low highlight the challenges faced, while recent quarterly results suggest some stabilisation in earnings. Investors analysing this stock will note the divergence between price trends and profit growth, alongside the company’s conservative leverage and fair valuation metrics.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →